Evidence map›Paper›PMID 37674228›Full record

ArticleJournal of neuroinflammation2023

RGS5 augments astrocyte activation and facilitates neuroinflammation via TNF signaling.

Shu Yin, Xin-Yue Ma, Ying-Feng Sun, Yan-Qing Yin, Ying Long, Chun-Lai Zhao, Jun-Wei Ma, Sen Li, Yan Hu, Ming-Tao Li and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Shu YinInstitute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science, Intelligence Technology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200031, China.
Xin-Yue MaDepartment of Pharmacology, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
Ying-Feng SunCenter for Brain Disorders Research, Center of Parkinson's Disease, Capital Medical University, Beijing Institute for Brain Disorders, Beijing, 100053, China.
Yan-Qing YinInstitute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science, Intelligence Technology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200031, China.
Ying LongDepartment of Pharmacology, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
Chun-Lai ZhaoInstitute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science, Intelligence Technology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200031, China.
Jun-Wei MaDepartment of Pharmacology, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China.
Sen LiInstitute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science, Intelligence Technology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200031, China.
Yan HuGuangdong Provincial Key Laboratory of Brain Function, Disease, Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, China.
Ming-Tao LiGuangdong Provincial Key Laboratory of Brain Function, Disease, Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, China.
Gang HuDepartment of Pharmacology, Nanjing University of Chinese Medicine, Nanjing, 210023, Jiangsu, China. ghu@njucm.edu.cn.
Jia-Wei ZhouInstitute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science, Intelligence Technology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200031, China. jwzhou@ion.ac.cn.ORCID http://orcid.org/0000-0002-1844-9178
Chinese Academy of Sciences · CNNanjing University of Chinese Medicine · CNSun Yat-sen University · CNCapital Medical University · CNNantong University · CN

Funding

Alabama Neuroscience Blueprint Core CenterP30NS057098 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROTH, KEVIN A · 2006 to 2010
$9.5M
ANALYSES AND APPLICATIONS OF GLIAL FIBRILLARY ACIDIC PROR01NS039055 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BRENNER, MICHAEL · 1999 to 2010
$2.6M
NINDS NIH HHS P30 NS057098NINDS NIH HHS R01 NS039055
6 · The paper itself

Abstract

Astrocytes contribute to chronic neuroinflammation in a variety of neurodegenerative diseases, including Parkinson's disease (PD), the most common movement disorder. However, the precise role of astrocytes in neuroinflammation remains incompletely understood. Herein, we show that regulator of G-protein signaling 5 (RGS5) promotes neurodegenerative process through augmenting astrocytic tumor necrosis factor receptor (TNFR) signaling. We found that selective ablation of Rgs5 in astrocytes caused an inhibition in the production of cytokines resulting in mitigated neuroinflammatory response and neuronal survival in animal models of PD, whereas overexpression of Rgs5 had the opposite effects. Mechanistically, RGS5 switched astrocytes from neuroprotective to pro-inflammatory property via binding to the receptor TNFR2. RGS5 also augmented TNFR signaling-mediated pro-inflammatory response by interacting with the receptor TNFR1. Moreover, interrupting RGS5/TNFR interaction by either RGS5 aa 1-108 or small molecular compounds feshurin and butein, suppressed astrocytic cytokine production. We showed that the transcription of astrocytic RGS5 was controlled by transcription factor early B cell factor 1 whose expression was reciprocally influenced by RGS5-modulated TNF signaling. Thus, our study indicates that beyond its traditional role in G-protein coupled receptor signaling, astrocytic RGS5 is a key modulator of TNF signaling circuit with resultant activation of astrocytes thereby contributing to chronic neuroinflammation. Blockade of the astrocytic RGS5/TNFR interaction is a potential therapeutic strategy for neuroinflammation-associated neurodegenerative diseases.

Indexed as

Neuroinflammatory DiseasesRGS ProteinsAnimalsAstrocytesInflammationSignal TransductionRGS ProteinsAstrocytesNeuroinflammationParkinson’s diseaseRGS5TNFR

Identifiers

PMID37674228
PMCPMC10481574
OpenAlexW4386479588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.